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Anxiety is a common problem in children and adolescents with autism spectrum disorder (ASD). This meta-analysis
aimed to systematically evaluate the evidence for the use of psychosocial interventions to manage anxiety in this
population. Cognitive behavioural therapy (CBT) was the primary intervention modality studied. A comprehensive
systematic search and study selection process was conducted. Separate statistical analyses were carried out for
clinician-, parent-, and self-reported outcome measures. Sensitivity analyses were conducted by removing any
outlying studies and any studies that did not use a CBT intervention. A subgroup analysis was performed to
compare individual and group delivery of treatment. Ten randomised control trials involving a total of 470 participants
were included. The overall SMD was d = 1.05 (95 % CI 0.45, 1.65; z = 3.45, p = 0.0006) for clinician- reported outcome
measures; d = 1.00 (95%CI 0.21, 1.80; z = 2.47, p = 0.01) for parent-reported outcome measures; and d = 0.65 (95%CI -0.10,
1.07; z = 1.63, p = 0.10) for self-reported outcome measures. Clinician- and parent-reported outcome measures showed
that psychosocial interventions were superior to waitlist and treatment-as-usual control conditions at post-treatment.
However, the results of self-reported outcome measures failed to reach significance. The sensitivity analyses did not
significantly change these results and the subgroup analysis indicated that individual treatment was more effective than
group treatment. The main limitations of this review were the small number of included studies as well as the clinical
and methodological variability between studies.
Keywords: Meta-analysis, Autism spectrum disorder/ASD, Anxiety, Child, Adolescent, Psychosocial intervention, Cognitive
behavioural therapy/CBTIntroduction
Autism Spectrum Disorder (ASD) is a neurodevelopmen-
tal disorder characterised by a triad of symptoms – deficits
in social communication, impaired social interaction and
lack of flexibility of thought and behaviour. These features
appear in early childhood and endure across the lifespan
[1]. ASD is an umbrella term introduced in the DSM-5 to
define a continuum of symptoms, formerly classified as
separate autistic disorders. These disorders included
Autistic disorder, Asperger syndrome (AS), and perva-
sive developmental disorder not otherwise specified* Correspondence: ashleyerobertson@icloud.com
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creativecommons.org/publicdomain/zero/1.0/(PDD-NOS) [2]. ASD has a prevalence of 1.16 % in the
general population [3].
Around 70 % of children with ASD also experience
psychiatric comorbidity [4], with one of the most com-
mon being anxiety [5]. Although anxiety in ASD is
present across the whole spectrum of the disorder, the
presentation seems to be affected by individual factors,
such as age, degree of social impairment and level of cog-
nitive functioning [6]. Prevalence rates of anxiety disorders
in typically developing children range between 2 and 27 %
[7], whereas rates of 11–84 % have been reported in the
children with ASD [6]. However, it should be noted that
rates vary substantially between studies due to varying
sampling methods and anxiety assessments [6]. The most
commonly reported anxiety disorders in the paediatricrticle distributed under the terms of the Creative Commons Attribution License
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pulsive disorder (OCD) (17 %) and social anxiety (17 %)
[8]. This distribution is similar to that seen in typically de-
veloping children, apart from OCD, which is more com-
mon in ASD [8, 9].
Due to a unique interaction between anxiety and core
ASD symptomology, the manifestation of anxiety in chil-
dren and adolescents with ASD differs in several ways
from anxiety seen in typically developing youth [10].
Anxiety in ASD is associated with more behavioural
problems, such as social avoidance, repetitive behaviours
and aggression [6, 11]. These maladaptive behaviours
may be difficult to differentiate from symptoms of ASD
[6, 9, 12] resulting in anxiety being underreported in this
population [13, 14]. As a result of the significant diag-
nostic overlap between anxiety disorders and core ASD
symptoms, it has been discussed whether anxiety should
be considered as part of ASD [8, 11]. However, ASD
may simply predispose to anxiety [9] since individuals
with ASD struggle to manage perceived threatening ex-
ternal stimuli due to deficits in executive functioning,
inherent difficulties understanding emotions, and prob-
lems with social and communication skills [9, 11, 15].
Furthermore, anxiety levels in ASD youth may be af-
fected by an increased or decreased sensitivity to sensory
stimuli and motor clumsiness [15].
Cognitive behavioural therapy (CBT) has been shown
to be effective in treating anxiety in typically developing
children and adolescents [16]. Furthermore, CBT can be
modified in a number of ways to make this treatment
modality more suitable for the ASD population [15].
Some of the issues that may affect the delivery of CBT
in ASD youth are difficulties responding to social cues
and engaging in reciprocal exchanges [17], as well as re-
duced verbal skills and difficulties processing figurative
meaning [15]. In addition, ASD youth may have difficul-
ties understanding and expressing emotions, and may
have reduced Theory of Mind (ToM) abilities, i.e. the
ability to identify their own and other individuals’
thoughts and emotions [18, 19]. It is essential that thera-
pists have insight into the difficulties people with ASD
may face in order to develop a therapeutic content, set-
ting and relationship that is tailored specifically for the
needs of this population [15].
The majority of research carried out to ascertain the
effectiveness of psychosocial interventions in the ASD
population is biased toward the high functioning end of
the spectrum [6]. This may be due to the logistical and
ethical issues that may arise when working with more
severely impaired individuals, including difficulties with
communication, giving informed consent, attending to
tasks and following instructions. The exclusion of youths
on the spectrum with cognitive limitations creates prob-
lems with generalising results to the Autism Spectrumas a whole. This needs to be taken into account when
interpreting study results. In the UK, individual or group
CBT is therefore recommended to manage anxiety in
children and young people with ASD if they have the ne-
cessary verbal and cognitive abilities [4].
The literature addressing treatment options for anxiety
in ASD youth has been constantly growing over the past
decade. At present, a considerable number of studies in-
vestigating psychosocial interventions for anxiety in chil-
dren and adolescents with ASD have been conducted.
Furthermore, comparable outcome measures have been
used in these studies, making it possible to perform a
meta-analysis. The primary treatment modality studied
in this meta-analysis was CBT, but it was considered im-
portant to also include other types of psychosocial
modalities, such as social skills interventions, since com-
ponents of these may be used to optimise content and
delivery of any anxiety management intervention aimed
at ASD youth.
The objective of this meta-analysis was to systematic-
ally review the evidence for the use of psychosocial
interventions to manage anxiety in children and adoles-
cents with ASD.Methods
Information sources and search strategy
This review was designed in accordance with the
PRISMA guidelines [20]. Two independent researchers
identified studies by searching electronic databases and
manually finding suitable published studies. The following
databases were searched: Web of Science, PsychINFO,
Embase, Medline and Cochrane Database of Systematic
Reviews (Cochrane Library). The search strategy included
terms such as ASD, auti*, child*, anxi*, psychotherap* and
cognitive behavi* therap*. It was limited to the title and
abstract or the topic, depending on the availability of
search options within each database. In addition, the
search was limited to journals in English with a publica-
tion year 2000–2013 due to practical reasons and the fact
that, to our knowledge, there were no studies published
prior to 2000 that met our inclusion criteria. The final
search was run on the 13th of November 2013.Eligibility criteria and study selection
Studies were included if they met the following criteria:
a) the study was published in English and between the
years 2000–2013; b) the study was a randomised control
trial (RCT); c) the patient population was children and/or
adolescents (age 0–18 years) with a primary diagnosis of
ASD and clinically significant anxiety symptoms; and d) at
least one outcome measure was a standardised continuous
measure of anxiety (parent-, clinician-, or self-reported).
Studies were screened based on the title and abstract. The
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vided in the Cochrane Collaboration Handbook [21].
Selection of outcome measures
Outcome measures were selected depending on their val-
idity and frequency of use. Judgement of the validity of
anxiety measures in the ASD population was based on
two recently published, methodologically rigorous reviews
[10, 11]. The frequency of use was considered important
to ensure maximum possible comparability between study
results. The selected clinician-reported outcome measures
were The Anxiety Disorders Interview Schedule – Child
/Parent version (ADIS-C/P) [22], The Pediatric Anxiety
Rating Scale (PARS) [23] and The Childhood Anxiety Sen-
sitivity Index - Anxiety (CASI-Anx) [24]. Spence Chil-
dren's Anxiety Scale – Parent version (SCAS-P) [25] and
Multidimensional Anxiety Scale for Children – Parent
version (MASC-P) [26] were used as parent-reported out-
come measures. Children's Anxiety Scale – Child version
(SCAS-C) [25], Multidimensional Anxiety Scale for Chil-
dren – Child version (MASC-C) [26], Revised Children's
Manifest Anxiety Scale (RCMAS) [27] and Social Inter-
action Anxiety Scale (SIAS) [28] were chosen as self-
reported outcome measures.
If a study used two of the selected outcome measures,
one of the measures was chosen for the analysis. Storch
et al. [29] reported both ADIS-C/P and PARS scores. Al-
though both measures are considered to be equally well
validated [11], PARS was selected for the purpose of this
review since the required ADIS-C/P scores were not
available. Chalfant et al. [30] included both SCAS-C and
MASC-C. The superiority of the SCAS-C or the MASC-
C in terms of validity was not clear [10, 11]. Therefore,
SCAS-C was chosen based on its frequency of use across
the reviewed studies. Although RCMAS and SIAS had not
been validated for use in the ASD population [10, 11], they
were used when studies lacked results from more vali-
dated outcome measures. Storch et al. [29] did not report
total RCMAS scores. Therefore, an average of the subscale
scores was used.
Data collection process and risk of bias within studies
Data extraction and risk of bias assessment was per-
formed according to the Cochrane Collaboration Guide-
lines [21]. The first author conducted the systematic
search and the second author verified inclusion/exclu-
sion of a subset of studies. Both authors independently
screened the originally selected studies and agreed on
which studies should be selected for the review. Data
extraction and risk of bias assessment were conducted
independently by the first and second author. Any dis-
crepancies between the authors’ ratings were arbitrated
by an independent party. Risk of bias within studies was
rated as high risk (bias that reduces reliability of results),low risk (bias that is unlikely to alter results) or unclear
(bias that raises doubt about reliability of results/insuffi-
cient information provided to make judgment). Only
methodological strengths and weaknesses that were rele-
vant for the results of this meta-analysis were considered
when assessing the risk of bias.
Selection bias was assessed based on adequate descrip-
tion of random sequence generation and concealment of
treatment group allocation. Due to the nature of the in-
terventions, blinding of participants and personnel was
not feasible in any of the included studies. Therefore, all
studies had a high risk of performance bias. Similarly,
detection bias was high for parent- and self-reported
outcome measures in all studies since blinding of these
measures was not viable. The studies that blinded
clinician-reported outcomes were scored as having a low
risk of detection bias. Attrition bias was assessed by
examining the reporting of withdrawals and drop-outs.
Outcome data were considered complete if there were
no missing pre- or post-treatment data, or if the study
authors had carried out an intent-to-treat analysis. Pro-
tocols were not available for any of the eleven studies.
Reporting bias was therefore evaluated purely based on
evidence of selective outcome reporting provided in the
study reports. No studies were excluded based on the
risk of bias assessment.
Summary measures and synthesis of results
Separate statistical analyses were carried out for clinician-,
parent-, and self-reported outcome measures. Standardised
mean difference (SMD) was used as the summary estimate
of treatment effect. This summary statistic was chosen be-
cause the analysis was performed on a variety of continu-
ous outcome measures. SMDs of -0.2,–0.5 and–0.8 were
deemed to be indicative of small, moderate and large ef-
fects respectively [31]. According to the Cochrane Collab-
oration Guidelines [21], the SMD can be calculated using
means and standard deviations either of final measure-
ments or of changes from baseline. Standard deviations of
changes were not reported in any of the included studies.
Therefore, SMD estimates were calculated based on the
post-treatment scores and standard deviations provided in
each study report. No adjustments of the scores were re-
quired since the direction of the scales was the same for all
outcome measures. The statistical significance level was set
at p < 0.05. Forest plots were used to illustrate results from
individual studies. In the case of multiple treatment arms,
such as in the study conducted by Sung et al. [32], the aver-
age score of both intervention groups was compared to the
control group score.
Higgin’s I2 [33] test was used to describe in percentage
the impact of heterogeneity on the effect estimates. It
was chosen over Cochrane’s Q Test since the latter has
low power when there are few studies [34]. An I2 of less
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and one substantially higher than 50 % was thought to re-
flect substantial heterogeneity [33]. Considerable statistical
heterogeneity was expected both due to clinical diversity
(variability in the participants, interventions and out-
comes) and methodological diversity (variability in study
design and risk of bias). As a result, a random-effects
model was chosen to estimate intervention effect (DerSi-
monian and Laird approach) [34]. All statistical analyses
were conducted using Review Manager 5.1 software [35].
Follow-up data was examined to determine whether the
effects of the treatment were maintained after the end of
the intervention. When examining follow-up results, suffi-
cient data was not available to conduct a statistical ana-
lysis. It was therefore assumed that the statistical analyses
conducted in the individual studies were correct.
Additional analyses
Due to the small number of studies in each review cat-
egory, publication bias could not be assessed formally by
using a funnel plot or statistical test [31, 36]. After dis-
cussion between the study authors, it was decided that
studies would be considered outliers if the SMD was 3
times greater than the next highest SMD in that cat-
egory. To analyse the effect outlying studies had on the
summary estimates, a sensitivity analysis was conducted
by removing any outlying studies in each category. Since
the eligibility of non-CBT interventions for this meta-
analysis was debatable, a sensitivity analysis was also per-
formed by removing any studies that did not use a CBT
intervention.
Due to the relatively limited research addressing psy-
chosocial treatment options for anxiety in children and
adolescents with ASD, it was deemed appropriate to in-
clude studies that used both individual and group inter-
ventions. To compare the effectiveness of these delivery
methods, a subgroup analysis was conducted by compar-
ing the confidence intervals of the summary estimates in
the two subgroups (individual +/- group therapy versus
group therapy only). No or minimal overlap between the
confidence intervals was considered indicative of statistical
significance. Subgroup analyses were only performed on
outcome measures if the overall summary estimate was
significant. The effects of other treatment moderators,
such as age, anxiety diagnosis, parental involvement and
types of intervention modifications, could not be per-
formed due to difficulty obtaining sufficiently comparable
data from the study reports.
Results
Study selection
The search of the databases yielded 1847 results, 575 of
which were duplicates. One paper was added which had
not yet been published at the time of the search [37].1272 records were screened based on the title and ab-
stract, 1242 of which were excluded. An additional three
were excluded due to a lack of full-text availability.
Twenty-seven full-text papers were assessed for eligibil-
ity. A total of ten studies met the inclusion criteria for
this review. A flow diagram of the study selection is
shown in Fig. 1.Study characteristics
A total of 470 (393 male, 72 female and five not reported)
participants aged 7–17 years were included. Nine studies
used a modified CBT intervention [29, 30, 32, 37–42] and
Schohl et al. used a social skills intervention [43]. Chalfant
et al., McConachie et al., Schohl et al., Sofronoff et al., and
Sung et al. delivered the intervention in a group format
(group sizes varying between 3 and 10 participants/group)
[30, 32, 37, 40, 43]. McNally Keehn et al., Storch et al., and
Wood et al. used individual therapy [29, 38, 42]. Reaven
et al. and White et al. used a combination of individual
and group therapy [39, 41]. The duration of the interven-
tions varied between 6 and 16 sessions and the length of
each session was 60 to 120 min.
Sung et al. [40] had an active control group in the
form of a social recreational group program. The rest of
the studies had waitlist or treatment-as-usual (WL/TAU)
control conditions [29, 30, 32, 37, 38, 40–43]. In the ma-
jority of the included studies, participants randomised to
the intervention, active control and/or WL/TAU condi-
tions were permitted to initiate and/or continue receiv-
ing pharmacological-, psychoeducational- and/or other
interventions during the study period [29, 30, 37–41].
Schohl et al., Sofronoff et al., and Wood et al. provided
no information about the additional interventions re-
ceived by participants. Conclusions about the extent to
which these supplementary interventions may have af-
fected the treatment effect could not be made due to in-
sufficient and inconsistent provision of information
across studies about the uptake of additional services.
The study authors established the ASD diagnoses either
by using The Autism Diagnostic Observation Schedule
(ADOS) [44] or by relying on a diagnosis made by a
paediatrician, psychiatrist or clinical psychologist. Since
the psychosocial interventions used in all ten studies re-
quired verbal communication skills, it can be assumed
that a certain level of language and cognitive ability was
necessary for participation in all included studies. In six
studies, the presence of an anxiety disorder was required
for inclusion [29, 30, 37, 38, 41, 42]. In all of these studies,
the diagnosis was determined using ADIS [21]. The rest of
the studies relied on parents providing an accurate report
of clinically significant anxiety symptoms or social difficul-
ties. A summary of study characteristics can be found in
Table 1.
Fig. 1 PRISMA flow diagram of study selection
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Selection bias – random sequence generation and
allocation concealment
Six of the included studies performed adequate random
sequence generation, either manually or generated by a
computer [29, 37, 39–42]. Chalfant et al, Sofronoff et al,
McNally Keehn et al, and Schohl et al. provided insuffi-
cient information about the randomisation process to
determine the extent to which this may have affected the
bias of these studies [30, 32, 38, 43]. McConachie et al.
performed satisfactory and complete allocation conceal-
ment [37]. In contrast, Chalfant et al. and Sung et al. did
not perform adequate allocation concealment [30, 40].
The remainder of the included studies indicated that
allocation concealment was implemented, but did not
provide sufficient information about the method of con-
cealment [29, 32, 38, 39, 41–43].
Performance and detection bias – blinding of participants,
personnel and outcome assessment
As previously stated, blinding of participants and personnel
was not possible in any of the included studies. Furthermore,blinding of parent- and self-reported outcome measures
was not feasible. In the studies conducted by Storch et al.,
McConachie et al., McNally Keehn et al., White et al., and
Wood et al., clinicians rating the ADIS or PARS were
blind to treatment allocation and these outcome measures
were therefore considered to have a low risk of detection
bias [29, 37, 38, 41, 42].
Attrition and reporting bias – incomplete outcome data and
selective outcome reporting
Reaven et al. and Schohl et al. were thought to have a
high risk of attrition bias since missing data was re-
moved from the study analysis [39, 43]. The remainder
of the included studies were deemed to have complete
outcome data [29, 30, 32, 37, 38, 40–42]. There was no
evidence of selective outcome reporting in any of the in-
cluded studies [29, 30, 32, 37–43].
Clinician reported outcome measures
Six studies involving a total of 208 patients (102 in the
treatment condition and 106 in the control condition) re-
ported a clinician-reported outcome measure. All studies
Table 1 A summary of study characteristics
Source Population No. of participants Age rangea Intervention Delivery Parental/caregiver
involvement
Comparison Outcome
measures
SMD
Chalfant
et al., 2007
[30]
Children with HFAD or
Asperger disorder and a
primary anxiety disorder.
47 (35 male, 12
female)
8-13 years (mean
10.8, SD 1.35)
CBT (n = 28) Group sessions
(6-8 children/group).
- WL/TAU (n = 19) SCAS-P 4.27
SCAS-C 2.64
McConachie
et al., 2013
[37]
Children with ASD and
at least one anxiety
disorder.
32 (28 male,
4 female)
9-13 years
and 11 months
CBT (n = 17) Group sessions
(no./group not reported).
Separate parallel
groups for parents.
WL/TAU (n = 15) ADIS-C 0.43
SCAS-P 0.20
SCAS-C 0.04
McNally
Keehn et al.,
2013 [38]
Children with an ASD
and at least one primary
anxiety disorder of SAD,
GAD or SoP.
22 (21 male,
1 female)
8-14 years (mean
11.26, SD 1.53)
CBT (n = 12) Individual sessions. - WL/TAU (n = 10) ADIS-P 1.35
SCAS-P 0.91
SCAS-C 0.47
Reaven
et al., 2012
[39]
Children with ASD and
clinically significant
anxiety symptoms.
50 (48 male,
2 female)
7-14 years (mean
10.4 years, SD 1.7)
CBT (n = 24) Children only group sessions
(3-6 children/ group), parent
and children sessions, parent-
child dyad sessions.
Parent and children group
sessions, parent only and
child only group sessions,
parent-child dyad sessions.
WL/TAU (n = 26) ADIS-P 0.60
Schohl et al.,
2013 [43]
Adolescents with ASD
and social problems.
63 (47 male, 11 female,
5 not specified)
11-16 years (mean
13.65 years, SD 1.50)
Social skills
intervention
(n = 34)
Group sessions (≤10
adolescents per group).
Separate parallel groups
for parents.
WL/TAU (n = 29) SIAS 0.16
Sofronoff
et al., 2005
[32]
Children with AS and
anxiety symptoms.
71 (62 male,
9 female)
10-12 years CBT Child only
(n = 23). CBT
Child + parent
(n = 25)
Group sessions (3 children/
group, allocated by age and
sex, with girls grouped
together)
Separate parallel groups
for parents (12-13 parents/
group)
WL/TAU (n = 23) SCAS-P 0.09
Storch et al.,
2013 [29]
Children with ASD and
a primary diagnosis of
SAD, GAD or OCD.
45 (36 male,
9 female)
7-11 years CBT (n = 24) Individual sessions. Separate parallel parent
sessions +/- parental
involvement in child-
focused components.
WL/TAU (n = 21) PARS 1.38
MASC 0.48
RCMAS 0.26
Sung et al.,
2011 [40]
Children and
adolescents with ASD
and anxiety-related
issues.
70 (66 male,
4 female)
9-16 years CBT (n = 36) Group sessions
(3-4 participants/ group).
- Social recreational
group program (n = 34).
SCAS-C 0.07
White et al.,
2013 [41]
Children with ASD and
at least one of SoP, GAD,
SP, or SAD.
30 (23 male,
7 female)
12-17 years (mean
14.58, SD 15 years)
CBT (n = 15) Individual and group
sessions (no./group
not reported).
Parent education and
coaching.
WL/TAU (n = 15) PARS 0.32
CASI Anx 0.37
Wood et al.,
2009 [42]
Children with ASD and
SAD, SoP or OCD.
40 (27 male, 13
female)
7–11 years, mean
9.20, SD 1.49
CBT (n =17) Individual sessions. 60 min of each session
spent with parents/family.
WL/TAU (n = 23) ADIS-C/P 2.47
MASC-P 1.21
MASC-C -0.03
SMD Standardised mean difference, HFAD High Functioning Autistic Disorder, SAD Separation anxiety disorder, GAD Generalised anxiety disorder, SoP Social phobia, SP Specific phobia, OCD Obsessive Compulsive Disorder, CBT
Cognitive behavioural therapy, WL/TAU Wait list/Treatment as usual, SCAS-C/P The Spence Children’s Anxiety Scale – Child/Parent, ADIS C/P The anxiety Disorders Interview Schedule – Child/Parent, SIAS The social Interaction
Anxiety Scale, PARS The Pediatric Anxiety Rating Scale, MASC The Multidimensional Anxiety Scale for Children, RCMAS The Revised Children's Manifest Anxiety Scale, CASI-Anx Child and Adolescent Symptom Inventory-4 ASD
Anxiety Scale
aMean and SD reported when data was available
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intervention condition compared to the control condi-
tion. The overall SMD was d = 1.05 (95 % CI 0.45, 1.65;
z = 3.45, p = 0.0006) which can be considered a large effect.
Based on these measures, the anxiety levels in the interven-
tion groups were significantly lower than those seen in the
WL/TAU groups at post-treatment. Considerable hetero-
geneity across the studies was detected (I2 = 74 %). A forest
plot illustrating these results is included as Fig. 2.
Parent reported outcome measures
Seven studies reported at least one of the selected parent-
reported outcome measures. These studies involved 283
participants (158 in the experimental condition and 125 in
the control condition). The overall SMD was d = 1.00
(95 % CI 0.21, 1.80; z = 2.47, p = 0.01) and the difference
between the intervention and control conditions at post-
treatment reached significance. There was significant het-
erogeneity across the included studies (I2 = 89 %). A forest
plot illustrating these results is included as Fig. 3. The
SMD reported by Chalfant et al. [30] was considered an
outlier since it was substantially higher than the ones re-
ported in the other studies. Once this outlier was re-
moved, the overall SMD decreased to 0.48 (95 % CI 0.14,
0.82; z = 2.80, p = 0.005). Although the summary estimate
decreased following removal of the outlying study, the
treatment effect remained significant.
Self-reported outcome measures
Self-reported outcome data from 297 participants (152 in
the intervention condition and 145 in the control condi-
tion) across seven studies was reported. The overall SMD
was d = 0.649 (95 % CI -0.10, 1.07; z = 1.63, p = 0.10) with
no significant difference between the experimental and
control conditions at post-treatment. There were high
levels of heterogeneity across the studies (I2 = 83 %). A for-
est plot illustrating these results is included as Fig. 4. Once
more, the SMD reported by Chalfant et al. [30] was anFig. 2 Forest plot of clinician-reported outcome measures with risk of biasoutlier and removal of this study reduced the overall SMD
to 0.14 (95%CI -0.11, 0.39; z = 2.80, p = 0.005). A sensitivity
analysis was carried out by removing Schohl et al. [43], the
only study that did not use a CBT intervention. This chan-
ged the overall SMD to 0.55 (95 % CI -0.16, 1.27; z = 1.51,
p = 0.13) and the difference between intervention and con-
trol conditions at post-treatment remained insignificant.
Group versus individual intervention
A subgroup analysis comparing individual +/- group
therapy versus group therapy only was conducted for
clinician- and parent-reported outcome measures. For
clinician-reported outcome measures, the summary esti-
mate for studies that used individual +/- group therapy
was 1.70 (95 % CI 1.01, 2.40; z = 3.37, p = 0.0007). This
can be compared to the summary estimate for studies that
used group therapy only which was 0.47 (95 % CI 0.08,
0.86; z = 2.36, p = 0.02). Although the difference between
experimental and control conditions at post-treatment
were significant for both individual +/- group therapy and
group therapy only, the confidence intervals for the two
subgroups did not overlap. This indicates that, according
to clinician-reported outcome measures, individual ther-
apy as part of the intervention improved its effectiveness.
For parent-reported outcome measures, the summary
estimate was 0.81 (95 % CI 0.36, 1.26; z = 3.56, p = 0.0004)
for studies that used individual +/- group therapy and
1.17 (95 % CI -0.28, 2.62; z = 1.58, p = 0.11) for those
that used group therapy only. The confidence intervals
clearly overlapped and it can therefore be concluded that,
for parent-reported outcome measures, individual therapy
components did not significantly increase the effectiveness
of the interventions. However, it should be noted that the
summary estimate for the studies that used individual +/-
group therapy reached significance and for those that used
group therapy only failed to do so. This implies that indi-
vidual therapy modules may be necessary to make therapy
beneficial.summary
Fig. 3 Forest plot of parent-reported outcome measures with risk of bias summary
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McConachie et al. [37], McNally Keehn et al. [38],
Sofronoff et al. [32], Storch et al. [29], and Sung et al.
[40] reported follow-up data. The follow-up results were
obtained between 6 weeks and 6 months after the end of
the intervention. In three studies, there were only follow-
up data available for the intervention condition since it
was considered unethical to withhold treatment from the
WL/TAU group. Therefore, only follow-up data from the
intervention groups were examined in this review. The
results in all five studies showed no statistically significant
(p < 0.05) difference between the post-treatment and
follow-up scores for any of the outcome measures. Al-
though the sample of studies that reported follow-up
data was small, the results indicate that the positive effects
of the intervention were maintained for some months
after the final session.
Discussion
Summary of evidence
This meta-analysis aimed to investigate the effectiveness of
psychosocial interventions for reducing anxiety in childrenFig. 4 Forest plot of self-reported outcome measures with risk of bias sumand adolescents with ASD. Clinician- and parent-reported
outcome measures showed that psychosocial interventions
were superior to WL/TAU control conditions at post-
treatment. In the parent-reported outcome measures cat-
egory, the SMD from Chalfant et al. [30] was identified as
an outlier. Although the summary estimate for parent-
reported outcome measures decreased following removal
of this study, the post-treatment difference between the ex-
perimental and control groups remained significant. It
should also be noted that Chalfant et al. [30] was rated as
having a high risk of bias in multiple domains of the risk of
bias assessment due to inadequate random sequence gener-
ation, allocation concealment, and blinding of participants,
personnel and outcome assessment. For self-reported out-
come measures, the difference between experimental and
WL/TAU groups at post-treatment failed to reach signifi-
cance. The subgroup analysis used to compare individual
and group delivery of treatment showed that individual +/-
group therapy was more effective than group treatment
alone, particularly for clinician-reported outcome measures.
The results from this meta-analysis indicate that the evi-
dence for using psychosocial interventions to managemary
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effect differs across anxiety informants.
Comparison of results to current literature
A meta-analysis of RCTs investigating the effectiveness of
CBTas a treatment for anxiety disorders in children and ad-
olescents with ASD was published by Sukhodolsky et al.
shortly after the study design for the present review had
been established [45]. Sukhodolsky et al. reported a treat-
ment effect of 1.21 (95 % CI 0.50, 1.97) for clinician-
reported outcome measures, 1.19 (95 % CI 0.23, 2.14) for
parent-reported outcome measures and 0.68 (95 % CI
-0.17, 1.54) for self-reported outcome measures. In addition
to the studies included in the meta-analysis conducted by
Sukhodolsky et al., the present study analysed two supple-
mentary studies – one that was published in late 2013 [37]
and one that used a social skills intervention rather than
CBT [43]. The addition of these studies consistently re-
duced the overall SMD and narrowed the 95 % CI, which
may indicate that the treatment effect reported by Sukho-
dolsky et al. may have been overestimated.
Treatment modality
CBT modified for children and adolescents with ASD
was the primary intervention modality studied in this
meta-analysis. However, the search was extended to
other types of psychosocial interventions since some of
these have been shown to be as effective as CBT in ASD
youth [14, 40]. The only other type of psychosocial inter-
vention that was identified in the search was a social
skills intervention. The association between social dis-
ability and anxiety in ASD youth seems to be bidirec-
tional. A higher IQ and greater social impairment has
been shown to be associated with more severe anxiety
symptoms, potentially due to the fact that individuals
with higher IQ are more aware of their social deficits
[23]. On the other hand, anxiety disorders can increase
social isolation and disability [15]. Components of social
skills interventions are essential as part of any psycho-
social intervention aimed at ASD youth and a social
skills approach to managing anxiety in ASD youth was
therefore considered valid for inclusion in this meta-
analysis.
Although psychosocial interventions seem to be effect-
ive in reducing anxiety compared to WL/TAU control
conditions, the literature involving an active control is
limited. Sung et al. [40] compared the effectiveness of
CBT and a social recreational group and found no signifi-
cant difference between the interventions and active con-
trol conditions at post-treatment and at 3- and 6-month
follow-up. Russell et al. [14] also failed to detect a signifi-
cant difference between the effectiveness of CBT and an
anxiety management intervention on OCD symptoms in
adults with ASD. Neither of these studies included a WL/TAU condition. Although these studies indicate that a
variety of psychosocial interventions may be equally ef-
fective in reducing anxiety symptoms in the paediatric
ASD population, further research with more homogenous
samples and multiple treatment arms will be necessary to
fully establish the most effective treatment modalities.
Individual versus group intervention
Psychosocial interventions for ASD youth can be delivered
in a variety of formats. Studies have been conducted using
interventions in a group or individual format (or a com-
bination of the two), but no study has yet compared these
delivery methods against one another [6]. Individual ther-
apy may be more flexible and allow treatment to be de-
signed according to the individual’s needs. Group therapy,
on the other hand, may be beneficial in terms of peer sup-
port and sharing of experiences. The results from the sub-
group analysis performed in this meta-analysis indicate
that individual +/- group therapy is more beneficial than
group therapy alone. For clinician-reported outcome mea-
sures, there was a significant difference between interven-
tion and control conditions at post-treatment for both
individual and group interventions. However, the sum-
mary estimate was significantly higher for the studies that
used individual therapy only. For parent-reported out-
come measures, the difference between intervention and
control conditions was significant in those studies that
used individual +/- group therapy. In contrast, in the studies
that used group therapy only, the difference between inter-
vention and control conditions failed to reach significance.
Modifications
Adapting psychosocial intervention programs to the needs
of children and adolescents with ASD may improve the de-
livery of and response to treatment [46]. These modifica-
tions aim to minimise potential barriers that may limit the
efficacy of treatment, including reduced ToM abilities, cog-
nitive inflexibility, executive function deficits and concrete
thinking [47]. The modification trends for CBT programs
include the use of visual aids, incorporation of child-
specific interests into the intervention, using highly struc-
tured sessions, and having a flexible number and length of
sessions [46, 47].
Parental involvement in psychosocial interventions
aimed at reducing anxiety in the paediatric population
has been shown to positively affect treatment outcome
in both typically developing children [48] and children
with Asperger syndrome [41, 49]. Further studies have
suggested that parenting and family factors, such as fam-
ily accommodation, are associated with treatment out-
comes [14, 30]. It is important to consider the potential
benefits of parental engagement in therapy targeted at
the ASD population. Firstly, if parents are taught to
become co-therapists, there may be reinforcement and
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ment [32]. Secondly, involvement of parents may reduce
parental anxiety and provide the necessary communica-
tion and coping skills to reduce the child’s anxiety [40].
Self-reported outcome measures
Self-reported outcome measures are used as they are
thought to provide reliable information about an individ-
ual’s health and illness [50]. The use of self-reported mea-
sures in the paediatric population has become increasingly
common. However, research of its efficacy is lacking [51].
In this review, parent- and clinician-reported outcome
measures showed a greater treatment effect than self-
reported measures which failed to reach significance. This
finding mirrors results from recent studies of multiple in-
formant agreement on anxiety measures in typically devel-
oping children [16] and children with ASD [52].
The reporting trends of different anxiety informants
may reflect an actual difference in the perceived effects
of the treatment between clinicians, parents and children.
However, this inconsistency may be caused by other fac-
tors, which makes the use of self-reported outcome as-
sessment questionable in paediatric populations. Children
may lack the general cognitive abilities, self-awareness and
understanding of health-related concepts to accurately re-
port these types of outcome measures [53]. Furthermore,
there is a general lack of understanding of how heath and
illness perceptions are expressed by children at different
stages of development [54].
In the paediatric ASD population, the use of self-reported
measures can be especially challenging [11]. A proportion
of the ASD population do not have the necessary commu-
nication and cognitive skills to conceptualise their thoughts,
emotions and behaviours, as well as identify internal states
such as worry and fear [11, 49]. Furthermore, individuals
with ASD may not be able to distinguish between their feel-
ings of anxiety from their experience of core ASD symp-
toms [7]. The anxiety symptoms may therefore be reported
inaccurately. Measures of anxiety reported by primary care-
givers are often considered more reliable in ASD youth
[49]. However, if the child lacks expressive language skills,
even caregivers may struggle to separate anxiety and ASD
symptomology [11].
Choice of outcome measures
The presentation of anxiety in the paediatric ASD popu-
lation is fundamentally different from the anxiety seen in
typically developing children and there is a general lack
of means to separate anxiety from core ASD symptomol-
ogy [10]. Therefore, outcome measure tools developed
to measure anxiety in typically developing children may
not be adequate at capturing the unique nature of anxiety
in an ASD population. Furthermore, the definition of a
successful outcome in the anxious ASD population mayinclude components that are not relevant for typically de-
veloping children, such as social and communication
skills, and level of participation [11].
All the outcome measures selected for this review
were developed to measure anxiety in typically develop-
ing children. There is some evidence that SCAS-C/P,
SCARED-C/P, CASI, MASC-P, PARS and ADIS-C/P can
be used to accurately measure anxiety in ASD. There is,
however, some disagreement between studies regarding
which instruments have the most robust measurement
properties in the paediatric ASD population [10, 11].
Validated and sensitive instruments modified for use in
children and adolescents with ASD will be necessary to
improve comparability between study results as well as
progress in treatment development [11]. However, until
further psychometric research is carried out, the meas-
ure of anxiety in children and adolescents with ASD will
rely on instruments developed for typically developing
children.
Future research
Future research with larger sample groups and extended
follow-up will be necessary to determine the precise ef-
fectiveness of psychosocial interventions for reducing
anxiety in the ASD youth. Additional qualitative studies
as well as the use of active control groups will be necessary
to understand the specific components of psychosocial in-
terventions that are most effective. More experience is re-
quired to establish empirically validated treatment manuals
for use specifically in children and adolescents with ASD
and find ways in which these manuals can be modified for
different developmental stages. Future research will also
have to ascertain how psychosocial interventions can be
modified for lower functioning children and adolescents
with ASD. Finally, further development of outcome mea-
sures will be essential to produce more reliable results.
Limitations
The results of this review may not be generalisable to
the paediatric ASD population due to small samples, ex-
clusion of the lower functioning subsets of the spectrum
as well as limited representation of females and ethnic
minorities. Although blinding of participants, personnel
and most outcome assessments was not feasible, this
lack of blinding may bias the results (perhaps due to
wishful thinking and social pressure). It should also be
noted that the participants in these studies were self-
selected and therefore could have been drawn from an
unusually motivated population.
The main limitation of this review was the inclusion of
a relatively small number of studies due to the limited
research in this area. This made it impossible to statisti-
cally analyse certain aspects of the data, including publi-
cation bias. Further limitations included clinical and
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made it impossible to conduct meaningful subgroup ana-
lyses to assess the potential effects of age, anxiety diagnoses,
parental involvement and other factors on the treatment ef-
fect. In addition, there was a lack of studies in languages
other than English. Finally, although data extraction and
study analysis was conducted by two independent reviewers
using a well validated and structured manual, there was still
a certain level of subjectivity to the review process.
Conclusion
This meta-analysis aimed to systematically evaluate and
summarise the evidence for using psychosocial interven-
tions to manage anxiety in children and adolescents with
ASD. Clinician- and parent-reported outcome measures
showed that psychosocial interventions were superior to
WL/TAU control conditions at post-treatment and indi-
vidual therapy seemed to be more effective than group
treatment. For self-reported outcome measures, the differ-
ence between experimental and WL/TAU groups at post-
treatment failed to reach significance. However, more
methodologically rigorous research will be necessary to
ascertain the precise potential of psychosocial interven-
tions to reduce anxiety in the paediatric ASD population.
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